Following recent string of failures in Parkinson's, hopes now on prasinezumab
The Parkinson’s disease (PD) pipeline has been hit significantly with a string of failures among its most anticipated mid-stage pipeline candidates.
This news presents a challenge for similar disease-modifying therapies (DMTs) undergoing development, such as Roche’s (ROG: SIX) prasinezumab. It also amplifies that a major unmet need remains in bringing DMTs and neuroprotective agents to this market, which is currently dominated by symptomatic treatments, says data and analytics company GlobalData.
Roche is developing prasinezumab with Ireland-based biotech Prothena (Nasdaq: PRTA), which earned a $60 million clinical milestone payment upon first patient dosed in this study, and is eligible to receive additional payments of up to $380 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze